Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lymphoma, Follicular

ClinicalTrials.gov lists 1,870 trials for Lymphoma, Follicular or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 107.

MeSH D008224 Neoplasms Neoplasm C04 C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 443 Phase 1/2 Phase 1/2 183 Phase 2 Phase 2 518 Phase 2/3 Phase 2/3 15 Phase 3 Phase 3 203 Phase 4 Phase 4 31 Not applicable Not applicable 274 Observational Observational 199 Phase 1 Phase 1 443 Phase 1/2 Phase 1/2 183 Phase 2 Phase 2 518 Phase 2/3 Phase 2/3 15 Phase 3 Phase 3 203 Phase 4 Phase 4 31 Not applicable Not applicable 274 Observational Observational 199

Trials per phase (log scale)

2 more sections with rows

1,870 of the 1,870 trials are tagged with Lymphoma, Follicular itself; the rest are tagged with a narrower condition beneath it.

Get the Lymphoma, Follicular report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lymphoma, Follicular trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 89

1990: 4 trials (Not applicable 1, Phase 2 3) 1991: 2 trials (Phase 2 2) 1992: 5 trials (Phase 2 3, Phase 1/2 1, Phase 1 1) 1993: 4 trials (Observational 1, Phase 3 2, Phase 2 1) 1994: 6 trials (Phase 3 3, Phase 2 1, Phase 1 2) 1995: 9 trials (Phase 3 3, Phase 2 3, Phase 1/2 1, Phase 1 2) 1996: 15 trials (Observational 2, Phase 2 7, Phase 1 6) 1997: 34 trials (Not applicable 2, Phase 3 8, Phase 2/3 1, Phase 2 10, Phase 1/2 3, Phase 1 10) 1998: 45 trials (Not applicable 1, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 20, Phase 1/2 3, Phase 1 12) 1999: 59 trials (Not applicable 4, Phase 3 7, Phase 2 20, Phase 1/2 5, Phase 1 23) 2000: 59 trials (Observational 1, Not applicable 5, Phase 3 8, Phase 2 25, Phase 1/2 5, Phase 1 15) 2001: 39 trials (Observational 1, Not applicable 2, Phase 3 8, Phase 2 13, Phase 1/2 2, Phase 1 13) 2002: 41 trials (Observational 2, Not applicable 5, Phase 3 5, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 15) 2003: 36 trials (Observational 2, Not applicable 7, Phase 3 5, Phase 2 7, Phase 1/2 4, Phase 1 11) 2004: 60 trials (Observational 2, Not applicable 6, Phase 3 8, Phase 2/3 1, Phase 2 23, Phase 1/2 5, Phase 1 15) 2005: 61 trials (Observational 5, Not applicable 5, Phase 4 2, Phase 3 8, Phase 2 21, Phase 1/2 10, Phase 1 10) 2006: 48 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 6, Phase 2 20, Phase 1/2 4, Phase 1 10) 2007: 77 trials (Other 1, Observational 8, Not applicable 5, Phase 4 1, Phase 3 9, Phase 2 31, Phase 1/2 5, Phase 1 17) 2008: 72 trials (Observational 16, Not applicable 4, Phase 4 2, Phase 3 4, Phase 2 25, Phase 1/2 8, Phase 1 13) 2009: 51 trials (Other 1, Observational 8, Not applicable 5, Phase 4 2, Phase 3 4, Phase 2 15, Phase 1/2 5, Phase 1 11) 2010: 65 trials (Observational 8, Not applicable 7, Phase 4 4, Phase 3 6, Phase 2 21, Phase 1/2 7, Phase 1 12) 2011: 55 trials (Observational 4, Not applicable 4, Phase 4 2, Phase 3 9, Phase 2 19, Phase 1/2 5, Phase 1 12) 2012: 44 trials (Observational 8, Not applicable 4, Phase 4 2, Phase 3 12, Phase 2 5, Phase 1/2 3, Phase 1 10) 2013: 56 trials (Observational 5, Not applicable 5, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 12, Phase 1/2 6, Phase 1 16) 2014: 53 trials (Observational 2, Not applicable 6, Phase 4 2, Phase 3 10, Phase 2 10, Phase 1/2 8, Phase 1 15) 2015: 53 trials (Observational 2, Not applicable 9, Phase 3 6, Phase 2/3 1, Phase 2 14, Phase 1/2 11, Phase 1 10) 2016: 56 trials (Observational 4, Not applicable 7, Phase 3 2, Phase 2/3 2, Phase 2 11, Phase 1/2 14, Phase 1 16) 2017: 75 trials (Observational 12, Not applicable 13, Phase 3 8, Phase 2 15, Phase 1/2 12, Phase 1 15) 2018: 60 trials (Observational 8, Not applicable 9, Phase 3 1, Phase 2 17, Phase 1/2 2, Phase 1 23) 2019: 59 trials (Observational 10, Not applicable 9, Phase 4 4, Phase 3 3, Phase 2 13, Phase 1/2 8, Phase 1 12) 2020: 62 trials (Observational 5, Not applicable 5, Phase 4 1, Phase 3 1, Phase 2/3 2, Phase 2 20, Phase 1/2 14, Phase 1 14) 2021: 81 trials (Observational 10, Not applicable 21, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 18, Phase 1/2 6, Phase 1 18) 2022: 81 trials (Observational 12, Not applicable 25, Phase 4 2, Phase 3 10, Phase 2 13, Phase 1/2 6, Phase 1 13) 2023: 89 trials (Observational 16, Not applicable 21, Phase 3 7, Phase 2 14, Phase 1/2 8, Phase 1 23) 2024: 84 trials (Observational 13, Not applicable 26, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 22, Phase 1/2 3, Phase 1 13) 2025: 82 trials (Observational 18, Not applicable 25, Phase 3 6, Phase 2/3 1, Phase 2 16, Phase 1/2 1, Phase 1 15)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 68
2025 82
2024 84
2023 89
2022 81
2021 81
2020 62
2019 59
2018 60
2017 75

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 89 trials starting in 2026 and about 86 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 189 trials still running at the 2026-10-09 snapshot; registered median of 38 months across 1,259 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lymphoma, Follicular trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 443
Phase 1/2 183
Phase 2 518
Phase 2/3 15
Phase 3 203
Phase 4 31
Not applicable 274
Observational 199
Expanded access 3
Unknown 1

How many Lymphoma, Follicular trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 43
Recruiting 202
Enrolling by invitation 13
Active, not recruiting 122
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lymphoma, Follicular trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 107
Novartis Pharmaceuticals 21
Hoffmann-La Roche 18

Which drugs are being tested for Lymphoma, Follicular? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 282
Cytoxan 224
Prednisone 63
Melphalan 56

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 137
Peripheral blood stem cell transplantation 114
Filgrastime (G-CSF) 91
Etoposid 83
X: Lenalidomide 75

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lymphoma, Follicular trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 684 99
Febrile neutropenia 513 98
Pyrexia 418 70
Neutropenia 398 56
Neutrophil count decreased 371 39

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lymphoma, Follicular? (412)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. Lancet (London, England) 2026 Yes
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet (London, England) 2026 Yes
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood advances 2025 Yes
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. Clinical pharmacology and therapeutics 2025 Yes
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood 2025 Yes

Showing 5 of 412 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (78)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Follicular lymphoma Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Follicular lymphoma Annual incidence 1-9 / 100 000 United Kingdom GB Unspecified
Follicular lymphoma Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Follicular lymphoma Annual incidence 1-9 / 1 000 000 Lithuania Not stated Unspecified
Follicular lymphoma Annual incidence 1-9 / 100 000 Portugal Not stated Exact

Showing 5 of 78 prevalence observations.

Start your 14-day trial Email me the first 50 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Follicular lymphoma 545 Exact Orphanet Rare Disease Ontology (ORDO)
Follicular lymphoma 545 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages